News

Roivant developing treatment for coronavirus patients

The Basel-based pharmaceutical company Roivant Sciences wants to develop a special antibody for coronavirus patients. This is intended to help treat and prevent acute respiratory distress syndrome.

Roivant Sciences gives hope to patients with coronavirus through its developments. Image credit: CDC via Unsplash
Roivant Sciences gives hope to patients with coronavirus through its developments. Image credit: CDC via Unsplash

Roivant Sciences is working on the development of a monoclonal antibody by the name of gimsilumab, as detailed in a press release. This targets the cytokine GM-CSF. According to the company, new clinical evidence is revealing that there is a connection between GM-CSF and acute respiratory distress syndrome (ARDS) in coronavirus patients. ARDS is a serious complication related to coronavirus that can see patients hospitalized or necessitate the use of mechanical ventilation or other life-support measures.

Roivant Sciences has previously tested gimsilumab in non-clinical investigations as part of a Phase 1 study. Treatment with the antibody has so far “been associated with a favorable safety and tolerability profile”, the press release states. The company has now contacted the regulatory authorities in the USA, Europe and Asia, with the aim of driving forward the clinical development of this antibody.

“Targeting GM-CSF represents a promising strategy for curbing lung damage while allowing time for the virus to clear”, comments Elizabeth Volkmann from the US institute UCLA Health, in the press release. “It is my hope that gimsilumab will reduce mortality from COVID-19 and help improve the lives of those affected by this emerging public health crisis”, she explains further.

Roivant Sciences and its subsidiaries received support from BaselArea.swiss during their efforts to establish a presence in Basel.

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.

Download
Recommend us
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program